Income Statement
VYNE THERAPEUTICS INC.
VYNE
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY |
|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
0.60 | 0.50 | 0.42 | 0.50 | 14.76 | 20.99 | - | - | - |
|
Cost of Revenue
|
- | - | - | - | 3.35 | 1.39 | - | - | - |
|
Gross Profit
|
0.60 | 0.50 | 0.42 | 0.50 | 11.41 | 19.60 | - | - | - |
|
Operating Expenses
|
-57.64 | -84.86 | 29.68 | 34.77 | 79.44 | 133.08 | 76.24 | 65.18 | 34.18 |
|
Research & Development
|
19.24 | 30.95 | 16.31 | 18.39 | 24.96 | 43.53 | 53.76 | 52.99 | 29.01 |
|
Selling, General & Administrative
|
11.08 | 13.19 | 13.38 | 16.39 | 54.48 | 89.54 | 22.48 | 12.19 | 5.17 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - |
|
Operating Income
|
-29.72 | -43.64 | -29.26 | -34.27 | -68.03 | -113.48 | -76.24 | -65.18 | -34.18 |
|
Non-Operating Income
|
-2.99 | -3.83 | -1.39 | -0.34 | 5.75 | 142.35 | - | - | - |
|
Interest Income
|
- | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | 0.00 | 5.61 | 4.39 | - | - | - |
|
Other Non-Op Income / Expense
|
3.02 | 3.83 | 1.39 | 0.36 | -0.14 | -1.11 | 2.54 | 3.09 | - |
|
Income Before Tax
|
-26.73 | -39.80 | -27.87 | -33.93 | -4.58 | -44.38 | - | - | - |
|
Income Tax Expense
|
-0.25 | 0.03 | 0.58 | -10.72 | -0.45 | -0.26 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - |
|
Net Income
|
-26.48 | -39.83 | -28.45 | -23.21 | -73.33 | -255.57 | -73.70 | -51.45 | -29.08 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY |
|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - |
|
EBITDA
|
-29.70 | -43.63 | -29.26 | -34.17 | -67.92 | -113.13 | -76.24 | -65.18 | -34.18 |
|
Earnings Per Share (Basic)
|
-0.62 | -0.93 | -2.78 | -7.28 | 1.42 | - | - | - | - |
|
Diluted EPS
|
-0.62 | -0.93 | -2.78 | -7.28 | 1.42 | - | - | - | - |
|
Weighted Average Shares
|
42.77 | 42.59 | 10.27 | 3.19 | 51.47 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
42.77 | 42.59 | 10.27 | 3.19 | 51.47 | - | - | - | - |
|
Comprehensive Income
|
-26.50 | -39.84 | -28.43 | - | 0.00 | -0.01 | -73.58 | -51.49 | -29.10 |